Join us for a KOL Webinar, featuring David V. Sheehan MD, MBA, FACPsych, DLFAPA (University of South Florida College of Medicine) who will discuss the unmet medical needs in suicide and depression and provide insight into the existing treatment landscape.

The discussion, moderated by Mike Moyer (LifeSci Advisors), will highlight Seelos Therapeutics’ asset SLS-002 (intranasal racemic ketamine), currently in a registration directed study for Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD).

A live question and answer session will follow the formal presentations.